Comparison of CL Wear Between Two Allergy Drops

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison of two allergy drops for enhancing comfort and performance of contact lens wear

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Contact lens patients will instill allergy drops and subjective and objective tests will be performed

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Conjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

epinastine HCL and olopatadine HCL

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females \> 18 years old
* Mild to moderate dry eye symptoms
* Likely to complete all study visits and able to provide informed consent

Exclusion Criteria

* Current use of topical cyclosporine
* Known contraindications to any study medication or ingredients
* Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable)
* Ocular surgery within the past 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Milton M. Hom, OD, FAAO.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Milton M Hom, OD FAAO

Role: STUDY_DIRECTOR

Private Practice

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5316

Identifier Type: -

Identifier Source: org_study_id